STAT+: Merck suffers a setback in Europe over its new Keytruda formulation
In a setback for Merck, a Dutch court ordered a halt to the manufacturing and marketing of a subcutaneous formulation of Keytruda in several European countries.
<p>In a setback for Merck, a Dutch court ordered a halt to the manufacturing and marketing of a subcutaneous formulation of Keytruda in several European countries.</p>